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Department of Toxicology, Center for Pharmaceutical Research, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, B-1090 Brussels, BelgiumSummary lated by a plethora of mechanisms, including connexinBecause of their critical role as goalkeepers of hepatic homeosta-
sis, gap junctions are frequent targets in liver disease. This con-
cept has been demonstrated on many occasions in the light of
hepatocarcinogenesis. Relatively little focus has been put on the
fate of gap junctions in other liver pathologies, including hepati-
tis, liver ﬁbrosis and cirrhosis, cholestasis and hepatic ischemia
and reperfusion injury. The present paper provides an in-depth
description of the multiple changes in expression, localization
and function of connexins, the molecular constituents of gap
junctions. The use of connexins as biomarkers and therapeutic
targets in liver disease is also illustrated.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Gap junctions gather at the cell plasma membrane surface in
areas called plaques. They arise from the interaction of two hemi-
channels of neighboring cells, that on their turn are hexamers of
connexin (Cx) proteins. Connexins all share a similar structure,
consisting of four transmembrane domains, two extracellular
loops, one cytoplasmic loop, one cytoplasmic carboxytail and
one cytoplasmic aminotail (Fig. 1) [1–3]. The predominant conn-
exin species in the liver is Cx32, which is abundantly expressed
by hepatocytes and to a lesser extent by sinusoidal endothelial
cells. The latter cells, as well as the stellate cells, produce also
small quantities of Cx26 [4], while Cx43 is detectable in Kupffer
cells, stellate cells, sinusoidal endothelial cells, and cholangio-
cytes [4–6]. However, the presence of functional gap junctions
has only been demonstrated in hepatocytes and stellate cells
[4]. Gap junctional intercellular communication (GJIC) includes
the passive exchange between adjacent cells of small and hydro-
philic substances, such as second messengers [1–3], and is regu-Journal of Hepatology 20
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TNFa, tumor necrosis factor alpha.phosphorylation [7]. As such, hepatic GJIC, in particular between
hepatocytes, has been shown to drive a number of essential pro-
cesses, namely albumin secretion [8], glycogenolysis [9,10],
ammonia detoxiﬁcation [8], bile secretion [11,12], and biotrans-
formation [13,14]. Moreover, gap junctions are also key players
in liver development [3], liver cell growth [1], and liver cell death
[15]. Their ubiquitous involvement in the maintenance of hepatic
homeostasis may explain why gap junctions are frequently tar-
geted in stress situations. Thus far, this has been well docu-
mented during liver toxicity [2,16] and hepatocarcinogenesis
[2,16,17]. Indeed, several excellent review papers have described
the fate of connexins and their channels in liver cancer [18–23].
Less attention has been paid to the role of liver gap junctions in
a number of other relevant non-cancerous clinical situations,
including cholestasis, liver ﬁbrosis and cirrhosis, hepatitis and
systemic inﬂammation, and hepatic liver ischemia and reperfu-
sion injury. A state-of-the-art overview of these features is pro-
vided in the current paper, with emphasis on gap junctions
composed of Cx26, Cx32 and Cx43.Gap junctions in cholestasis
Cholestasis denotes any situation of impaired bile secretion with
concomitant accumulation of potentially noxious cholephiles in
the liver or in the systemic circulation [24]. Depending on the site
of the obstruction, a distinction is made between intrahepatic
and extrahepatic cholestasis. In humans, cholestasis can be
induced by a variety of factors, including several drug treatments
and hereditary mutations in drug transporter genes, and may
become manifested in a number of conditions, such as primary
sclerosing cholangitis and primary biliary cirrhosis [25,26]. A
popular experimental model of extrahepatic biliary obstruction
is common bile duct ligation in rat [25]. A handful of early studies
described a reversible decrease of the hepatic gap junction num-
ber upon bile duct ligation [27–29]. Later on, this was repeatedly
demonstrated to be accompanied by a rapid drop in amounts of
Cx32 mRNA [30] and protein levels [30–33], a process mediated
by the p38 mitogen-activated protein kinase (p38 MAPK) [30].
Hepatic Cx26 immunoreactivity also decreases following bile
duct ligation [30,31], though its mRNA content rather increases
[30]. In contrast, Cx43 protein is positively affected in this model
[30] and it has been reported that bile duct ligated heterozygous
Cx43+/ knock-out mice display less hepatic vein angiogenesis,
while other parameters, such as biliary duct hyperplasia, remain
unchanged [34]. Unlike Cx26 and Cx32, no changes in Cx4312 vol. 57 j 655–662
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Fig. 1. Molecular architecture of gap junctions. Gap junctions are grouped in plaques at the cell plasma membrane surface of two apposed cells, and are composed of 12
connexin proteins, organized as two hexameric hemichannels. The connexin protein is organized as four transmembrane domains (TM), two extracellular loops (EL), one
cytoplasmic loop (CL), one cytoplasmic aminotail (NT) and one cytoplasmic carboxytail (CT).
Reviewsteady-state protein levels are observed in the choledochocaval
ﬁstula rat model of complete biliary retention [31]. Effects on
Cx43 are also absent in estrogen-treated rats, which typically
develop intrahepatic cholestasis, and Cx32 production even
increases in this experimental model [31]. However, induction
of intrahepatic cholestasis in rats by phalloidin administration
adversely inﬂuences gap junctions and Cx32-positive spots, ﬁrst
in the pericentral region and subsequently throughout the entire
liver acinus [35]. Such contradicting results illustrate that the
outcome of the induced cholestasis response on hepatic connex-
ins depends on the nature of the trigger used. Furthermore, the
mechanisms that underlie the effects of cholestasis on gap
junctions remain obscure. Boucherie and colleagues reported that
cholestatic bile acids, such as taurolithocholic acid, taurolitho-
cholicsulfate acid, and taurochenodeoxycholic acid, dose-
dependently and reversibly inhibited GJIC between cultured
primary rat hepatocyte couplets. Choleretic bile acids, including
taurocholic acid and tauroursodeoxycholic acid, do not affect
gap junction activity in these cells. Taurolithocholicsulfate acid
also suppresses GJIC between normal rat cholangiocytes, which
only express Cx43, but not in cervical cancer cells stably transfec-
ted with Cx32 or Cx26. This shows not only that the presence of
bile transporters is crucial for inhibiting gap junctions, but also
that this effect is not connexin-speciﬁc. How this ultimately leads
to suppression of GJIC is unclear, though increases in calcium or
hydrogen concentration or protein kinase C-mediated phosphor-
ylation have been deﬁnitely excluded [36].Gap junctions in liver ﬁbrosis and cirrhosis
Hepatic ﬁbrosis occurs as a wound healing response, mainly
through accumulation of extracellular matrix proteins, to both656 Journal of Hepatology 201acute and chronic liver injury, and can be caused by a multitude
of factors, including drug treatment, infections, viruses, meta-
bolic, and cholestatic disorders. A central event in liver ﬁbrosis
is the transformation of stellate cells into a cell type with a more
myoﬁbroblast-like phenotype. This process is initiated by a num-
ber of stimuli, such as inﬂammatory and apoptotic signals. Liver
cirrhosis is considered as the most advanced stage of ﬁbrosis
and is typiﬁed by nodule formation, modiﬁcation in liver function
and blood ﬂow, and a considerable risk of liver failure [37,38].
Deterioration of the liver parenchyma is hereby also clinically
manifested as a decline in Cx32 amounts [39–41]. This has been
experimentally reproduced in rodents treated with carbon tetra-
chloride or thioacetamide, which are prototypical liver ﬁbrotic
agents [42–47]. During the early stage of centrilobular necrosis
induced by thioacetamide in the rat liver, gap junctions are still
present, but they disappear in the course of the subsequent
restorative proliferative response. Thereafter, gap junctions reap-
pear, ﬁrst in the perinecrotic region and eventually in all areas
[43]. This observation is in contradiction with what has been
observed in carbon tetrachloride-treated mice, where the loss
of Cx32 immunoreactivity was shown to recover in all regions
except in perinecrotic areas, especially those that strongly
express a-fetoprotein [46]. The deleterious effects of carbon tet-
rachloride on gap junctions only become evident at doses that
cause an increase in serum alanine aminotransferase (ALT) levels
[42,44,45,48], suggesting that hepatotoxicity provokes its delete-
rious outcome on gap junctions [42]. The required occurrence of
hepatotoxicity prior to the decay of gap junctions, both at func-
tional and structural levels, was also demonstrated in vitro,
namely in cultures of primary rat hepatocytes exposed to carbon
tetrachloride. This effect depends on biotransformation, as it is
prevented in the presence of a cytochrome P450 inhibitor [49].
Carbon tetrachloride not only reduces Cx32 protein levels, but2 vol. 57 j 655–662
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also induces a shift in its cellular localization from the cell plasma
membrane surface to the cytoplasm and nuclei of hepatocytes
[39,48]. This has also been reported for Cx26 and for Cx43 present
in sinusoidal endothelial cells [48]. Similar events have been
observed in cultures of spontaneously activated primary rat stel-
late cells, whereby both Cx26 and Cx43 reside in the perinuclear
region. Increased levels of Cx43 mRNA and protein as well as
enhanced Cx43 phosphorylation and GJIC have been also
observed in spontaneously activated stellate cells [4], which is
in line with the observed behavior of these cultured cells when
exposed to carbon tetrachloride [50]. Interestingly, stellate cells
establish heterologous communication with hepatocytes under
these conditions [51], while homologous GJIC in primary hepato-
cyte cultures is negatively affected by carbon tetrachloride [49].
This is in agreement with the general observation that Cx32,
expressed by hepatocytes, is lost, whilst Cx43, produced by stel-
late cells, is promoted during liver ﬁbrosis, a hallmark that has
been demonstrated both in vitro [4,50,52] and in vivo
[43,47,53,54], not only for carbon tetrachloride [4,42,44–46],
but also for several other ﬁbrotic stimuli. This in turn indicates
speciﬁc roles for cell type-speciﬁc connexins and associated GJIC
in ﬁbrogenesis. As for other pathological conditions in the liver,
the relevance of enhanced Cx43 production in hepatic ﬁbrosis
and cirrhosis raises some questions. In this respect, induction of
hepatic granulomas and concomitant ﬁbrogenesis in mice by
Schistosoma mansoni infection is associated with increased Cx43
protein production and elevated proliferative activity and colla-
gen content. In Cx43-deﬁcient mice, proliferative activity is
lower, while collagen content is higher. This suggests a role for
Cx43 in the process of granuloma formation [54]. Likewise,
repeated administration of carbon tetrachloride to Cx43-lacking
mice results in excessive liver ﬁbrosis, including tick irregular
collagen ﬁbers, compared with wild-type animals. These animals
present less necro-inﬂammatory lesions on liver parenchyma,
lower serum ALT and aspartate aminotransferase (AST) levels,
and less hepatocyte proliferation. Combined with the ﬁnding that
carbon tetrachloride induces cytoplasmic localization of Cx43 in
wild-type animals, the authors of this study concluded that
Cx43 fulﬁlls a key role in the regulation of hepatic ﬁbrogenesis
via a gap junction-independent mechanism. In addition, it has
been hypothesized that modiﬁed cell architecture and homeosta-
sis upon Cx43-deﬁciency could compromise the transit and
absorption of proliferative and toxic factors by hepatocytes,
which could explain lower proliferation and injury [54].Gap junctions in hepatitis and systemic inﬂammation
Several pathological conditions in the liver, including ﬁbrosis and
cirrhosis, and cholestasis, are associated with inﬂammation. As
such, low Cx32 protein levels have been detected in liver tissue
from hepatitis patients [39,40]. An acute status of inﬂammation
can be experimentally induced in animals by injection of lipo-
polysaccharide (LPS), a component isolated from the outer mem-
brane of Gram-negative bacteria that acts as an endotoxin.
Similar to hepatitis patients, decreased liver Cx32 amounts have
been measured in mice [55] and rats [31,56,57] as well as in iso-
lated perfused livers [58] treated with LPS. This is paralleled by
identical changes at the mRNA level [55,57–59], which in turn
results from increased Cx32 mRNA degradation [57,59] by short-Journal of Hepatology 201ening of its poly(A) tail [59]. Less consistent results have been
obtained for Cx26, which can be either downregulated [31,58]
or upregulated [55], whether or not accompanied by modiﬁca-
tions in its mRNA production [55,58]. This becomes even more
pronounced when using other inﬂammatory triggers, such as
the pro-inﬂammatory cytokines tumor necrosis factor alpha
(TNFa), interleukin 1 beta (IL-1b), and interleukin 6 (IL-6), both
in vitro [60] and in vivo [55]. In cultures of primary rat hepato-
cytes [31,47] and immortalized mouse hepatocytes [60], these
pro-inﬂammatory cytokines suppress GJIC and it has been dem-
onstrated that the concomitant reduction of Cx32 steady-state
levels is mediated by a MAPK/nuclear factor kappa beta (NF-jb)
signaling cascade [47]. In contrast, in primary rat stellate cultures
and primary rat Kupffer cell cultures exposed to IL-1b [4] and
LPS/interferon gamma (IFNc) [61], respectively, GJIC becomes
more intensiﬁed. This is associated with increased Cx43 produc-
tion, both at the translational and at the transcriptional level
[4,61]. In fact, upon inﬂammatory challenge, Cx43 protein moves
from the cytoplasm to the cell plasma membrane surface in Kupf-
fer cells, where it starts to form functional gap junctions [61].
Increases in Cx43 protein amounts have been also observed dur-
ing liver inﬂammation in vivo [31,61]. It is thought that this is
part of the activation of the macrophage activity of Kupffer cells
during inﬂammation, taking care of debris clearance and apopto-
sis of macrophages and damaged hepatocytes [61].Gap junctions in liver ischemia and reperfusion injury
Hepatic ischemia and reperfusion injury occurs in a variety of
clinical situations, including trauma, liver resection surgery, and
liver transplantation. The mechanism of liver damage after ische-
mia and reperfusion is complex and relies on an interplay of mul-
tiple pathways [62–64]. Changes in hepatocellular gap junction
ultrastructure are known to take place during ischemia in rat
in vivo [65]. In a rat model of partial liver ischemia and reperfu-
sion, Cx26 and Cx32 expression levels decreased during ischemia,
but were induced during the early reperfusion phase, which
holds true especially for Cx26. In later phases, deterioration of
connexin production was noticed. Identical changes were seen
in concentration of calcium, which is known to move intercellu-
larly through gap junctions [66]. In a similar experimental model,
it was found that the reductions in Cx32 mRNA and protein
amounts occur at different time points and are driven by different
posttranscriptional and posttranslational mechanisms in ische-
mic and non-ischemic liver areas during reperfusion [67]. In addi-
tion to a pronounced inﬂammatory response, a major factor that
contributes to ischemia and reperfusion injury includes the gen-
eration of oxygen-derived free radicals [62–64]. In this regard,
hydrogen peroxide caused a suppression of Cx32 protein levels
and GJIC in cultures of primary rat hepatocytes [68]. Hydrogen
peroxide and paraquat also induced oxidative stress and blocked
GJIC in primary mouse hepatocyte cultures [69]. Administration
of ochratoxin A to rats resulted in hepatotoxicity associated with
mild oxidative stress and the downregulation of Cx26, Cx32, and
Cx43 expression [70]. Cx32 production was equally compromised
by hepatic oxidative stress induced by administration of furan to
rats [53]. Oxidative stress in primary hepatocyte cultures was
found to be associated with different cis/trans regulation of the
Cx32 gene [71].2 vol. 57 j 655–662 657
Table 1. Effects of cholestasis on liver gap junctions. (See below-mentioned references for further information.)
Model Effect [Ref.]
Liver tissue from extrahepatic cholestasis patients ~ Gap junctions [82, 83]
Liver tissue from cholelithiasis patients ↓ Gap junctions [84]
Liver tissue from rats subjected to bile duct ligation ↓ Gap junctions [27, 28]
↓ Gap junctions (ligation)
↑ Gap junctions (recanalization)
[29]
↓ Cx32 protein (ligation)
↑ Cx32 protein (recanalization)
[33]
↓ Cx32 protein (p38 MAPK-mediated) [32]
↓ GJIC
↓ Cx26 protein 
↑ Cx26 mRNA
↓ Cx32 mRNA/protein 
[30]
↓ Cx26 protein 
↓ Cx32 protein 
↑ Cx43 protein
[31]
Liver tissue from rats treated with ethinyl estradiol ~ Gap junctions [85]
~ Cx26 protein
↑ Cx32 protein 
~ Cx43 protein
[31]
Liver tissue from rats treated with estradiol valerate ↓ Gap junctions [86]
Liver tissue from rats treated with phalloidin ↓ Gap junctions (pericentral)
↓ Cx32 protein
[35]
↓ Cx26 protein 
↓ Cx32 protein 
~ Cx43 protein
[31]
Liver tissue from cdc42 ↓ Gap junctions [87]
Liver tissue from lamprey undergoing biliary atresia ↓ Gap junctions [88]
Primary rat hepatocyte doublet cultures exposed to 
taurolithocholic acid/taurolithocholicsulfate acid/
taurochenodeoxycholic acid
↓ GJIC [36]
Normal rat cholangiocyte culture exposed to
taurolithocholicsulfate acid
↓ GJIC [36]
Liver tissue from rats subjected to choledochocaval fistula
-deficient mice
Cdc42, cell division cycle 42; Cx, connexin; GJIC, gap junctional intercellular communication; p38 MAPK, p38 mitogen-activated protein kinase.
", upregulation; ;, downregulation; , no modiﬁcation.
ReviewConclusions and perspectives
Inherent to their key role in liver homeostasis, gap junction func-
tionality is typically altered during aberration of this critical equi-
librium as exempliﬁed in the current review for a number of
pathological situations (Tables 1–3). Although exceptions do
exist, it can be generalized from this literature survey that Cx32
expression progressively deteriorates upon progression of liver
disease, while Cx43 production is gradually promoted. This
becomes even more pronounced in liver cancer, which is fre-
quently the end stage of chronic liver pathology [39,72]. There-
fore, Cx43 could be considered as a hepatic stress connexin and
could serve a diagnostic role as a biomarker in clinical settings.
With respect to this, it has been recently demonstrated that alter-
ations in connexin expression, particularly increased Cx43 pro-
duction, is an early indicator of chronic kidney disease. Cx43
was hereby suggested to amplify calcium signaling and to spread
inﬂammatory messengers [73]. A similar scenario may take place
in the liver. The exact role of gap junctions in hepatic stress situ-
ations and its functional implications are, however, unclear. Thus,
no differences in the expression of positive (e.g. b-ﬁbrinogen) and658 Journal of Hepatology 201negative (e.g. albumin) acute phase transcripts were observed
following administration of cytokines and LPS to Cx32-deﬁcient
mice compared with wild-type mice, suggesting that Cx32 does
not play a role in experimental liver inﬂammation [55]. Correa
and colleagues showed that Cx32-based gap junctions are indis-
pensable in model animals during the recovery from hypoglyce-
mia and cholestasis upon LPS-triggered systemic inﬂammation
[56]. On the other hand, increases in serum ALT and AST levels
and the occurrence of cell death were less manifested in Cx32
dominant-negative mutant transgenic rats that received carbon
tetrachloride in comparison with their wild-type counterparts,
pointing to a role for GJIC in the dissemination of cell injury
and cell death signals [74]. Further research in this direction is
necessary and needs to take into account the possible involve-
ment of new players in the gap junction arena, including hemi-
channels and pannexin channels. Indeed, hemichannels not
only are gap junction building blocks, but also provide a route
for communication between the cytoplasm and the extracellular
environment [75]. A similar type of channels is formed by pan-
nexins (Panx), that are connexin-like proteins of which three
family members have been characterized in humans [76], with2 vol. 57 j 655–662
Table 2. Effects of hepatic ﬁbrosis and cirrhosis on liver gap junctions. (See below-mentioned references for further information.)
Model Effect [Ref.]
Liver tissue from cirrhosis patients ↓ Cx32 protein [40, 41]
↓ Cx32 protein 
Cx32 in cytoplasm
[39]
Liver tissue from mice treated with carbon tetrachloride ↓ Cx32 protein [46]
~ Cx26 mRNA/protein
Cx26 in cytoplasm/nuclei (hepatocytes)
~ Cx32 mRNA/protein
Cx32 in cytoplasm/nuclei (hepatocytes)
↑ Cx43 protein
Cx43 in cytoplasm (sinusoidal endothelial cells)
~ Cx43 mRNA
[48]
Liver tissue from rats treated with carbon tetrachloride ↑ Gap junctions [89]
↓ GJIC
↓ Cx32 protein 
[42]
↓ Cx32 protein [44]
↓ Cx32 protein 
↑ Cx32 mRNA
[45]
↑ Cx43 protein (stellate cells) [4]
Liver tissue from rats treated with thioacetamide ↓ Cx32 protein [43, 47]
Liver tissue from rats treated with furan ↓ Cx32 protein [53]
Liver tissue from mice treated with Schistosoma mansoni ↑ Cx43 protein [54]
Primary rat hepatocyte-stellate cell co-culture from rats treated with 
carbon tetrachloride
↑ GJIC (hepatocyte-stellate cells) [51]
Primary rat stellate cell cultures from rats treated with carbon tetrachlo-
ride
↑ GJIC
↑ Cx43 protein 
↑ Cx43 phosphorylation
[50]
Primary rat hepatocyte doublet cultures exposed to carbon tetrachloride ↓ GJIC [49]
Primary mouse hepatocyte cultures exposed to carbon tetrachloride ~ GJIC [90]
Primary mouse hepatocyte cultures exposed to 
methotrexate
~ GJIC [90]
Primary rat hepatocyte cultures subjected to iron loading ↓ GJIC
↓ Cx32 protein
[52]
Activated primary rat stellate cell cultures ↑ GJIC
↑ Cx26 mRNA/protein
Cx26 in perinuclear area
↑ Cx43 mRNA/protein
↑ Cx43 phosphorylation
Cx43 in plasma membrane/perinuclear area
[4]
Cx, connexin; GJIC, gap junctional intercellular communication.
", upregulation; ;, downregulation; , no modiﬁcation.
JOURNAL OF HEPATOLOGYPanx1 and Panx2 being expressed in the liver [77]. Both hemi-
channels and pannexin channels are known to act as pathological
pores, though speciﬁc information in relation to the liver is scarce
[78]. Furthermore, hepatic connexins are known to interact with
tight junction proteins, including occludin and zonula occludens
proteins, which contribute to the pathogenesis of liver disease,
in particular cholestasis, upon dysregulation [79]. Besides serving
diagnostic purposes, connexins and their channels are also inter-
esting therapeutic targets. Dexamethasone, for instance,
counteracts decreased Cx32 protein levels and GJIC induced by
pro-inﬂammatory cytokines in cultured hepatocytes [60]. Car-
benoxolone, a prototypical GJIC inhibitor, suppressed DNA syn-
thesis and collagen production in cultures of activated stellate
cells [80]. As dysregulated GJIC underlies a multitude of diseases,
a large-scale search for speciﬁc GJIC modifying tools, especially
those that are applicable in vivo, is currently ongoing [81]. It
can be expected that this will result in a number of agents that
can be potentially used for the clinical treatment of liver diseases.Journal of Hepatology 201Key Points 
• Gap junctions and their connexin building stones undergo 
• Connexins can be used as biomarkers for the diagnosis 
and prognosis of liver disease
• Gap junctions are promising therapeutic targets for the 
clinical treatment of liver disease
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Table 3. Effects of hepatitis and systemic inﬂammation on liver gap junctions.
Model Effect [Ref.]
Liver tissue from chronic hepatitis patients ↓ Cx32 protein [40]
↓ Cx32 protein 
Cx32 in cytoplasm
[39]
Liver tissue from rats treated with LPS ↓ GJIC
↓ Cx32 protein 
[56]
↓ Cx32 protein 
↓ Cx32 mRNA (degradation)
[57]
↓ Cx32 mRNA (degradation/shortening poly(A) tail) [59]
↓ Cx26 protein 
↓ Cx32 protein 
↑ Cx43 protein
[31]
↑ Gap junctions (Kupffer cells) [61]
Isolated perfused liver from rats treated with LPS ↓ GJIC
↓ Cx26 protein 
↑ Cx26 mRNA 
↓ Cx32 protein 
↓ Cx32 mRNA
[58]
Liver tissue from mice treated with 
LPS/TNFα/IL-1β/IL-2/IL-6 
↑ Cx26 mRNA/protein (LPS/TNFα)
~ Cx26 mRNA/protein (IL-1β/IL-2/IL-6)
↓ Cx32 protein (LPS/TNFα/IL-1β/IL-2/IL-6)
↓ Cx32 mRNA (LPS)
~ Cx32 mRNA (TNFα/IL-1β/IL-2/IL-6)
[55]
Immortalized mouse hepatocytes exposed to 
TNFα/IL-1/IL-6
↓ GJIC
↑ Cx26 protein (IL-6)
↑ Cx26 mRNA/protein (TNFα/IL-1)
~  Cx26 mRNA (IL-6)
↓ Cx32 protein
~ Cx32 mRNA
[60]
Primary rat hepatocyte-Kupffer cell co-culture exposed to LPS ↓ GJIC [31]
Primary rat Kupffer cell cultures exposed to LPS/IFNγ ↑ GJIC
↑ Cx43 mRNA/protein
Cx43 in plasma membrane 
[61]
Primary rat hepatocyte culture exposed to TNFα/IL-1β/IL-6 ↓ GJIC
~ Cx26 protein
~ Cx32 protein
[31]
Cx, connexin; GJIC, gap junctional intercellular communication; IFNc, interferon gamma; IL-1(b)/2/6, interleukin 1 (beta)/2/6; LPS, lipopolysaccharide; NF-jb, nuclear factor
kappa beta; MAPK, mitogen-activated protein kinase; TNFa, tumor necrosis factor alpha.
", upregulation; ;, downregulation; , no modiﬁcation.
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